Switch theme
Sign up to access all valuation multiples
Prestige Biologics Co Ltd is a CDMO-dedicated company that provides solutions of development and manufacturing tasks throughout the stages from the research/development, engineering, clinical production, commercial production, clinical support, and IND & BLA filing of biopharmaceutical products. Its product candidate includes HD201 (Herceptin Biosimilar).
2015
n/a
Last FY Revenue $1.6M
Last FY EBITDA -$4.6M
$277M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Prestige Biologics achieved revenue of $1.6M and an EBITDA of -$4.6M.
Prestige Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Prestige Biologics valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.6M | XXX | XXX | XXX |
| Gross Profit | XXX | -$6.3M | XXX | XXX | XXX |
| Gross Margin | XXX | -400% | XXX | XXX | XXX |
| EBITDA | XXX | -$4.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -294% | XXX | XXX | XXX |
| EBIT | XXX | -$24.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | -1541% | XXX | XXX | XXX |
| Net Profit | XXX | -$21.4M | XXX | XXX | XXX |
| Net Margin | XXX | -1354% | XXX | XXX | XXX |
| Net Debt | XXX | $104M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Prestige Biologics's stock price is KRW 3880 (or $3).
Prestige Biologics has current market cap of KRW 300B (or $218M), and EV of KRW 381B (or $277M).
See Prestige Biologics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $277M | $218M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Prestige Biologics has market cap of $218M and EV of $277M.
Prestige Biologics's trades at 175.7x EV/Revenue multiple, and -59.8x EV/EBITDA.
Equity research analysts estimate Prestige Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Prestige Biologics's P/E ratio is not available.
See valuation multiples for Prestige Biologics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $218M | XXX | $218M | XXX | XXX | XXX |
| EV (current) | $277M | XXX | $277M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 175.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -59.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -11.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -10.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -22.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPrestige Biologics's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Prestige Biologics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Prestige Biologics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Prestige Biologics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -294% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 89% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 429% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1141% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prestige Biologics acquired XXX companies to date.
Last acquisition by Prestige Biologics was XXXXXXXX, XXXXX XXXXX XXXXXX . Prestige Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Prestige Biologics founded? | Prestige Biologics was founded in 2015. |
| Where is Prestige Biologics headquartered? | Prestige Biologics is headquartered in South Korea. |
| Is Prestige Biologics publicy listed? | Yes, Prestige Biologics is a public company listed on KRX. |
| What is the stock symbol of Prestige Biologics? | Prestige Biologics trades under 334970 ticker. |
| When did Prestige Biologics go public? | Prestige Biologics went public in 2021. |
| Who are competitors of Prestige Biologics? | Similar companies to Prestige Biologics include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Prestige Biologics? | Prestige Biologics's current market cap is $218M |
| Is Prestige Biologics profitable? | Yes, Prestige Biologics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
